Latest Strategic Collaborations News

Streamplay Studio Limited has reported a third consecutive cash-flow positive quarter, driven by the blockbuster launch of Winter Burrow and key Tier-1 platform partnerships including Amazon. The company’s diversified publishing and subscription model underpins a robust financial position heading into 2026.

Nanoveu Limited has marked significant progress in its 16nm ECS-DoT edge-AI system-on-chip development, secured a strategic $7.5 million capital raise, and earned top honours at CES 2026, positioning itself for commercial breakthroughs in 2026.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

The Garvan Institute has won a $3 million MRFF grant to conduct pivotal pancreatic cancer studies, including one evaluating Syntara’s amsulostat combined with chemotherapy. Recruitment is slated to begin mid-2026 across major NSW cancer centres.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Nanoveu Limited has raised A$7.5 million through a strategic placement to accelerate the commercial rollout of its cutting-edge EMASS ECS-DoT semiconductor technology, including a rapid 16nm chip tape-out and live drone validation.

Talga Group has entered a strategic development agreement with German battery innovator V4Smart to co-develop high-performance graphite anodes for fast-charging lithium-ion batteries, aiming for commercial readiness by 2027.

Vitrafy Life Sciences has entered a 12-month exclusive partnership with IMV Technologies to integrate cryopreservation technologies, securing up to A$930k in fees and milestone payments.

Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.

Zeotech Limited is set to validate its zeolite-based methane biofilter in a six-month on-site trial at a North Burnett landfill, aiming to curb emissions by over 90%. This marks a critical step from lab success to real-world application, supporting Australia’s climate goals.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Tasman Resources has increased its investment in Eden Innovations through a $250,000 conditional share placement, raising its ownership to 13.95% and securing additional options. This move replaces further financial support and positions Tasman shareholders to benefit from Eden’s growth potential.